Skip to main content
. 2018 Mar 22;86(4):e00869-17. doi: 10.1128/IAI.00869-17

TABLE 2.

Characteristics, identified mutations, and genome sequence accession numbers of isolates analyzed in this studyg

Isolate Source (alias) Yr isolated PFGE profile Detected mutations GenBank accession no. Reference
B199 FDA (105) 1935 CDC059 fhaB: IS481, pos 3124; 28 nonsynonymousb; 127-kb duplicationc; 34.5-kb duplicationc CP022361 This study
J014a Minnesota, USA 2014 CDC237 RD16_14675: del AGGCCC, pos 479 CP012135 This study
J042 NIH (325) 1947 CDC232 bipA: IS481, −88d; RD16_14485: C10T; RD16_09925: C352T; 57.5-kb duplicationc CP019869 This study
J043 NIH (326) 1947 CDC372 bvgS: ins C, pos 3312; fhaB: IS481, pos 9865; 58 nonsynonymousb; 6 IS481b CP016887 This study
J199a Colorado, USA 2014 CDC237 fhaB: del G, pos 1087; bipA: 5′-UTR C/Te CP011245 This study
J365 California, USA 2014 CDC002 28-kb ptx-ptl delf; fhaB: IS481, pos 9865 CP013867 This study
10536 Sanofi vac 1939 CDC054 NA CP012128 37
B1917 Netherlands 2000 NT NA CP009751 78
B1920 Netherlands 2000 NT NA CP009752 78
B3582 Sweden 2009 NT fhaB: ins G, pos 1087 CP011443 35
B3585 Sweden 2009 NT Unknown CP011444 35
C393 Chinese vac 1951 CDC052 NA CP010963 12
E476 Tohama I 1954 CDC232 NA CP010964 12
FR3749 France 2007 CDC046 NA CP010966 45
H378 California, USA 2010 CDC253 NA CP010839 12
H559 California, USA 2010 CDC253 NA CP010844 12
H622 California, USA 2010 CDC217 NA CP010847 12
H627 California, USA 2010 CDC217 NA CP010962 12
I468 Vermont, USA 2012 CDC002 NA CP010251 12
I472 Vermont, USA 2012 CDC046 NA CP010253 12
I483 Vermont, USA 2012 CDC237 NA CP010256 12
I518 Vermont, USA 2012 CDC002 NA CP010259 12
I521 Vermont, USA 2012 CDC237 NA CP010260 12
I762a New York, USA 2013 CDC002 NA CP011745 36
I959a Oregon, USA 2012 CDC253 NA CP011746 36
I979 New York, USA 2013 CDC306 NA CP010966 45
J010a Connecticut, USA 2013 CDC237 NA CP012085 36
J174a Colorado, USA 2014 CDC237 NA CP013900 36
a

Isolates collected through Enhanced Pertussis Surveillance (61).

b

Details listed in Data Set S1 in the supplemental material.

c

Details listed in Data Set S3 in the supplemental material.

d

Details listed in Data Set S2 in the supplemental material.

e

164 bp upstream of the translational start site at position 1147474 (position 1169765 in E476).

f

Described by Williams et al. (45).

g

Abbreviations: del, deletion; ins, insertion; pos, position; vac, vaccine; UTR, untranslated region; NT, not tested; NA, not applicable.